5 Best Genomics Stocks to Buy Now

2. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 37

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is involved in developing genome editing capabilities to cure diseases by leveraging the CRISPR/Cas9 technology. The Cambridge, Massachusetts-based company is applying two methodologies. The first approach is an in-vivo program, which uses CRISPR injected intravenously to edit particular genes that are the root cause of the disease. Meanwhile, under the ex-vivo program, CRISPR is used to create the therapeutic by manipulating the human cells to aid in the cure of cancers and autoimmune diseases.

NTLA-2001 is the lead candidate for Intellia Therapeutics, Inc. (NASDAQ:NTLA) targeted towards the treatment of transthyretin amyloidosis (ATTR). The medication has received orphan drug status from the US Food and Drug Administration (FDA). Furthermore, Intellia Therapeutics, Inc. (NASDAQ:NTLA) has announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has given the go-ahead to expand to bring in patients from amyloidosis cardiomyopathy (ATTR-CM). This is a positive development because 200,000 to 500,000 patients are suffering from ATTR-CM as opposed to only 50,000 patients suffering from ATTR.

Furthermore, Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received approval from the New Zeeland and the UK regulatory authorities regarding the first-in-human trial of NTLA-2002, which is an in-vivo therapeutic targeted towards the treatment of hereditary angioedema. Meanwhile, in the US, the drug is in the dose-escalation and expansion stage of the Phase I/II trial. In a research note that came out on November 16, Tony Butler at Roth Capital anticipates Intellia Therapeutics, Inc. (NASDAQ:NTLA) to induct 55 patients into the study and also highlighted these catalysts as the basis for a Buy rating with a $180 target price.

Carillon Tower Advisers discussed its stance on Intellia Therapeutics, Inc. (NASDAQ:NTLA) in its Q2 2021 investor letter.

“Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.”